Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
9.38
+0.30 (3.30%)
Oct 3, 2025, 4:00 PM EDT - Market closed
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts that cover Nurix Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $29.07, which forecasts a 209.91% increase in the stock price over the next year. The lowest target is $16 and the highest is $41.
Price Target: $29.07 (+209.91%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 31, 2025.
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 6 |
| Buy | 8 | 8 | 8 | 7 | 7 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 16 | 16 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $32 → $30 | Buy | Reiterates | $32 → $30 | +219.83% | Jul 31, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $17 → $16 | Hold | Maintains | $17 → $16 | +70.58% | Jul 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $36 → $34 | Strong Buy | Maintains | $36 → $34 | +262.47% | Jul 14, 2025 |
| UBS | UBS | Strong Buy Maintains $30 → $26 | Strong Buy | Maintains | $30 → $26 | +177.19% | Jul 10, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $32 → $30 | Buy | Maintains | $32 → $30 | +219.83% | Jul 10, 2025 |
Financial Forecast
Revenue This Year
95.24M
from 54.55M
Increased by 74.59%
Revenue Next Year
62.72M
from 95.24M
Decreased by -34.15%
EPS This Year
-3.04
from -2.88
EPS Next Year
-3.70
from -3.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 118.6M | 99.8M | |||
| Avg | 95.2M | 62.7M | |||
| Low | 61.3M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 117.4% | 4.7% | |||
| Avg | 74.6% | -34.1% | |||
| Low | 12.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.86 | -2.07 | |||
| Avg | -3.04 | -3.70 | |||
| Low | -3.35 | -4.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.